Microba Life Sciences Limited
Microba Life Sciences Limited MAP.AX Peers
See (MAP.AX) competitors and their performances in Stock Market.
Stock Comparison
MAP.AX vs IDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, IDX.AX has a market cap of 952.87M. Regarding current trading prices, MAP.AX is priced at $0.17, while IDX.AX trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas IDX.AX's P/E ratio is 128.00. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, MAP.AX is more volatile compared to IDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs HLS.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, HLS.AX has a market cap of 838.68M. Regarding current trading prices, MAP.AX is priced at $0.17, while HLS.AX trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas HLS.AX's P/E ratio is -1.20. In terms of profitability, MAP.AX's ROE is -0.48%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, MAP.AX is less volatile compared to HLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs ACL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, ACL.AX has a market cap of 620.19M. Regarding current trading prices, MAP.AX is priced at $0.17, while ACL.AX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas ACL.AX's P/E ratio is 21.07. In terms of profitability, MAP.AX's ROE is -0.48%, compared to ACL.AX's ROE of +0.18%. Regarding short-term risk, MAP.AX is more volatile compared to ACL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs MVF.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, MVF.AX has a market cap of 325.35M. Regarding current trading prices, MAP.AX is priced at $0.17, while MVF.AX trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas MVF.AX's P/E ratio is -83.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, MAP.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs GSS.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, GSS.AX has a market cap of 147.64M. Regarding current trading prices, MAP.AX is priced at $0.17, while GSS.AX trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas GSS.AX's P/E ratio is -6.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, MAP.AX is less volatile compared to GSS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs PEB.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, PEB.AX has a market cap of 64.95M. Regarding current trading prices, MAP.AX is priced at $0.17, while PEB.AX trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas PEB.AX's P/E ratio is -2.00. In terms of profitability, MAP.AX's ROE is -0.48%, compared to PEB.AX's ROE of -0.57%. Regarding short-term risk, MAP.AX is more volatile compared to PEB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs IIQ.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, IIQ.AX has a market cap of 44.10M. Regarding current trading prices, MAP.AX is priced at $0.17, while IIQ.AX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas IIQ.AX's P/E ratio is -5.64. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, MAP.AX is more volatile compared to IIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs CTE.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, CTE.AX has a market cap of 34.90M. Regarding current trading prices, MAP.AX is priced at $0.17, while CTE.AX trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas CTE.AX's P/E ratio is 17.88. In terms of profitability, MAP.AX's ROE is -0.48%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, MAP.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs BDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, BDX.AX has a market cap of 27.45M. Regarding current trading prices, MAP.AX is priced at $0.17, while BDX.AX trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas BDX.AX's P/E ratio is -2.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, MAP.AX is more volatile compared to BDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs LDX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, LDX.AX has a market cap of 20.21M. Regarding current trading prices, MAP.AX is priced at $0.17, while LDX.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas LDX.AX's P/E ratio is -2.70. In terms of profitability, MAP.AX's ROE is -0.48%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, MAP.AX is more volatile compared to LDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs RHY.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, RHY.AX has a market cap of 17.97M. Regarding current trading prices, MAP.AX is priced at $0.17, while RHY.AX trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas RHY.AX's P/E ratio is -6.20. In terms of profitability, MAP.AX's ROE is -0.48%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, MAP.AX is less volatile compared to RHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs GTG.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, GTG.AX has a market cap of 9.45M. Regarding current trading prices, MAP.AX is priced at $0.17, while GTG.AX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, MAP.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs IBX.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, IBX.AX has a market cap of 2.42M. Regarding current trading prices, MAP.AX is priced at $0.17, while IBX.AX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas IBX.AX's P/E ratio is -0.24. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IBX.AX's ROE of +0.55%. Regarding short-term risk, MAP.AX is less volatile compared to IBX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs WFL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, WFL.AX has a market cap of 1.48M. Regarding current trading prices, MAP.AX is priced at $0.17, while WFL.AX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, MAP.AX's ROE is -0.48%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, MAP.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.
MAP.AX vs SHL.AX Comparison
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 76.13M. In comparison, SHL.AX comparison data is unavailable. Regarding current trading prices, MAP.AX is priced at $0.17, while SHL.AX trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -5.67, whereas SHL.AX's P/E ratio is N/A. In terms of profitability, MAP.AX's ROE is -0.48%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, Volatility data is not available for a full comparison. MAP.AX has daily volatility of 4.82 and SHL.AX has daily volatility of N/A.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDX.AX | $2.56 | -0.39% | 952.87M | 128.00 | $0.02 | +2.27% |
| HLS.AX | $1.16 | -25.00% | 838.68M | -1.20 | -$0.96 | +35.76% |
| ACL.AX | $3.16 | -0.94% | 620.19M | 21.07 | $0.15 | +3.96% |
| MVF.AX | $0.84 | +1.83% | 325.35M | -83.50 | -$0.01 | +6.11% |
| GSS.AX | $0.65 | -3.70% | 147.64M | -6.50 | -$0.10 | N/A |
| MAP.AX | $0.17 | +3.03% | 76.13M | -5.67 | -$0.03 | N/A |
| PEB.AX | $0.08 | -5.88% | 64.95M | -2.00 | -$0.04 | N/A |
| IIQ.AX | $0.40 | N/A | 44.10M | -5.64 | -$0.07 | N/A |
| CTE.AX | $0.72 | +0.70% | 34.90M | 17.88 | $0.04 | +2.80% |
| BDX.AX | $0.08 | -1.33% | 27.45M | -2.50 | -$0.03 | N/A |